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A B S T R A C T
In the current study the ability of copper complex to exert multiple biological activities is combined with the
pharmacological action of sertraline (SerH2Cl, antidepressant drug). The hydrated and anhydrous forms of the
tetrachlorocuprate(II) salts, namely (SerH2)2[CuCl4]·½H2O and (SerH2)2[CuCl4], were synthesized and char-
acterized by physicochemical methods. The crystal structures were determined by X-ray diffraction methods.
The hydrate complex crystallizes in the monoclinic P21 space group with a= 8.0807(2) Å, b= 36.2781(8) Å,
c= 12.6576(3) Å, β= 95.665(2)°, and Z= 4 molecules per unit cell and the un-hydrate in P21 with
a= 13.8727(6) Å, b= 7.5090(3) Å, c= 18.618(1) Å, β= 104.563(6)°, and Z= 2. It has been suggested that
Cu(II) ions might be critical in the development of mood disorders, showed potent biocidal activity, and also
acted as analgesic adjuvant. To improve sertraline efficiency, the antidepressant and analgesic activities of the
complex have been assessed in rats denoting a marked synergistic effect. Antithyroid and antimicrobial activities
were also evaluated. Because depressive disorders and hyperthyroidism diseases led to an oxidative stress state,
antioxidant capability has also been tested. The complex behaved as a good superoxide radical scavenger
(IC50 = 6.3 × 10−6 M). The ability of the complex to act as bromoperoxidase mimic was assessed. A pseudo-
first order constant of k= 0.157 ± 0.007 min−1 has been determined. The complex evidences promising
biological-pharmacological activities and the albumin binding studies showed a Kb of 2.90 × 103 M−1 showing
an improvement in the uptake of sertraline by albumin at 8 h incubation (time required for effective interaction
of sertraline with the protein).
1. Introduction
Medicinal inorganic chemistry has become a research area of great
interest. It comprises many anticancer agents, antibiotics, anti-
bacterials, antivirals, antiparasitics, antiarthritics, and radiosensitizing
agents, among others [1]. Indeed, metal-based drugs offer an alter-
native therefore impacting strongly over the human health since the
discovery of the antitumor activity of cisplatin. The advantage of this
kind of new compounds is based in the fact that the changes in the
coordination sphere affect the uptake, biodistribution, and metabolism.
They are different from the organic drugs and result in other active
metal-containing complex with improved beneficial action [[1,2].].
Among many metal complexes, the copper complexes are well re-
cognized because of their biological action as anticancer [3], anti-
microbials [4], and antioxidant agents [5]. However, different salts of
tetrachlorocuprate(II) have not yet been thoroughly studied in relation
to their biological properties. Usually, these complexes were studied
because of the interest in their thermocromic behavior [6], magnetic
properties [7], polymorphism [8], and catalytic properties [9].
In recent years we have investigated the antidepressant activity of
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compounds containing typical antidepressant (sertraline) or anti-
oxidants. They include studies on coordination Zn(II) complexes
[10–12]. aimed to improve their efficiency. Recently, the involvement
of essential elements in depression have been reviewed, resulting in
detailed information about preclinical and clinical data which links
them with mental disorders, the nutrient in a diet, serum levels, etc.
[13,14]. Furthermore, information about elements that exert anti-
depressant or anxiolytic effects when they are administered as simple
salts or in combine treatments has been compiled. Indeed, it has been
suggested that Cu(II), as a regulator of several biological process, might
be critical in the development of mood disorders. Although there are
contradictory results, literature shows that Cu(II) deficiency in mice,
rats and lambs results in significant decreases in brain noradrenaline
levels involved in the pathophysiology of depression. In addition, in
some antidepressant treatments the serum copper levels were sig-
nificantly reduced [14]. Considering this information, one of our initial
hypotheses was that the new sertraline-based copper complex may
behave as a good antidepressant. It might avoid reduction of the copper
levels and result in a synergistic effect, which is provoked by the
combination of this metal with the antidepressant. As an additional
contribution of the present work, the antinociceptive activity of the
(SerH2)2[CuCl4] (Sertralonium tetrachlorocuprate(II)) was evaluated
keeping in mind the reported analgesic properties of antidepressants
and the one showed by copper complexes [15,16].
Other pharmacological studies that are currently carried out in our
group are related to the development of compounds which can poten-
tially act as antithyroid agents and the study of their mechanism of
action. These compounds may either act by interfering with thyroid
peroxidase (TPO) enzyme or by forming stable complexes with iodine.
The formation of stable charge-transfer complexes with the compound
of our interest and the iodine molecule were studied at the beginning of
our research. In this context, a series of methimazole-derived complexes
were considered, as well as the demonstration that sertraline efficiently
acted as an iodine captor [17,18]. According to these considerations,
the determination of the antithyroid activity of the sertraline-derived
complex and lactoperoxidase inhibition experiments were measured.
It is worth noting that there seems to be a link between the de-
pressive disorder with both hyperthyroidism diseases and oxidative
stress. In both cases, there is an increment in the reactive oxygen spe-
cies (ROS) and interference in the superoxide dismutase function
[19,20]. Therefore, it would be very interesting to see if copper com-
plex could also scavenge free radicals. To this purpose, we evaluated
the antioxidant activity of the complex.
Considering that some antidepressants (including both sertraline
and copper) displayed antimicrobial activities, we also tested if the new
compound was able to present and/or improve this behavior [21,22].
In addition, tetrachlorocuprate complex ions have been widely used
as catalyst-reaction media in a variety of hydrocarbon conversions, such
as chlorinations, oxychlorinations, oxidations and oxidative dehy-
drogenations [23,24]. They have also been used in other catalytic re-
actions in which the alkane, alkene were obtained as products. For this
reason, the transition metal salts were used together with the Grignard
reagent [25]. Thus, there is an intrinsic possibility that the complex
behaves as a biological catalyst. Bearing in mind this possibility, the
mimicking of the peroxidase activity was also evaluated for this com-
pound.
Finally, since the ability of drugs to bind or interact with albumin is
essential for their pharmacokinetic and pharmacodynamic properties,
the bovine serum albumin ability of binding to the compound was as-
sessed by fluorescence and UV–Vis spectroscopies.
2. Experimental section
2.1. Methods and materials
CuCl2·2H2O was obtained from Biopack (Bs As, Argentina) and
sertraline hydrochloride (C17H17Cl2N, SerH2+Cl−) from Sigma
Chemical Company (St. Louis, MO). All the solvents used were from
analytical grade and used as supplied. Elemental analysis for carbon,
nitrogen and hydrogen was performed using a Carlo Erba EA1108
analyzer. A Shimadzu system (model TG-50 and DTA-50), working in
an oxygen flow of 50 mL·min−1 and at a heating rate of 10 °C·min−1
has been used for the thermogravimetric analysis. Sample quantities
ranged between 10 and 20 mg. Al2O3 was used as a DTA standard.
FTIR spectra of powdered samples as pressed KBr pellets were
measured with a Bruker IFS 66 FTIR-spectrophotometer in the
4000–400 cm−1 frequency range. Spectra were recorded with a fre-
quency resolution of 4 cm−1 and 64 scans were averaged for each
spectrum. The data were analyzed using OPUS program (Bruker Optics,
USA).
Raman spectra were collected on a Raman Horiba Jobin Yvon
T64000 (confocal microscopy Olympus BX41) spectrophotometer with
a laser power of 400 mW and a spectral resolution of 4 cm−1. Each
spectrum was obtained as an average of 10 scans collected in the
4000–400 cm−1 range. Spectra plotting, processing, normalizations,
manipulations, and evaluation were carried out with the OPUS software
(Bruker Optics, Germany). A EPR Bruker ESP300 spectrometer oper-
ating at the X-band and equipped with standard Oxford Instruments
low-temperature devices (ESR900/ITC4) was used to record the spec-
trum of the solid state complex at different temperatures. Anisotropic X
and Q band EPR spectra of the solid were recorded between 290 and
5 K. A computer simulation of the EPR spectra was performed using the
program WINEPR SimFonia (version 1.25, Bruker Analytische
Messtecnik, 1996). Magnetic susceptibility measurements on poly-
crystalline samples were performed also in the 290–5 K temperature
range with a Quantum Design MPMS-7 superconducting quantum in-
terference device magnetometer and using an applied field of 0.1 T.
Diamagnetic corrections of the constituent atoms were estimated from
Pascal's constants.
UV–vis spectra determinations were recorded with a Shimadzu
2600/2700 spectrophotometer. This instrument was also used to collect
the diffuse reflectance spectra, employing MgO as a standard.
Fluorescence spectra were obtained using a Shimadzu (RF6000) lumi-
nescence spectrometer equipped with a pulsed xenon lamp.
2.2. Synthesis
2.2.1. (SerH2)2[CuCl4]·½H2O and (SerH2)2[CuCl4]
Under continuous stirring, 1 mmol of sertraline hydrochloride was
dissolved in a mixture of 50 mL of ethyl acetate and 25 mL of 96%
ethanol and then the solution was heated to boiling until the solute was
entirely dissolved. A solution containing 0.5 mmol of CuCl2·2H2O was
prepared in 1 mL of 37% HCl and it was slowly drop-wise added to the
first solution of sertraline hydrochloride. Then, the resulting solution
was boiled for 30 min to halve the volume. This solution was then se-
parated into two portions: one portion was cooled to room temperature
and the other one placed in the refrigerator for a week to favor the
formation of single crystals suitable for structural X-ray diffraction
work. Crystals grown from both solutions were filtered out and washed
with 96% ethanol. Elemental analysis: (i) hydrated salt
(SerH2)2[CuCl4]·½H2O (C34 H37 Cl8 Cu N2 O0.5). Calculated: 49.2%C,
3.4%N, 4.5%H; Found: 49.4%C, 3.6%N, 4.6%H (ii) Un-hydrate salt
(SerH2)2[CuCl4] (C34 H36 Cl8 Cu N2). Calculated: 49.7%C, 3.4%N, 4.4%
H. Found: 50.0%C, 3.6%N, 4.3%H. Thermogravimetric analysis
(oxygen atmosphere, 50 mL/min): (i) hydrate salt: the water loss fin-
ishes at relatively high temperatures, (endothermic peak, 189 °C) and
the water release involved a percentage of mass loss of 1.2% in con-
cordance with the calculated one (Δωcalc = 1.1%). After dehydration,
the compound degraded in a series of two consecutive TG steps ob-
served up to 200 °C. Weight constancy is attained 750 °C and the weight
of the remaining solid residue was of 9.7%, in good agreement with the
expected value of 9.6%. The presence of CuO in the residue was
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confirmed by FTIR spectroscopy.(ii) Un-hydrate salt: similar behavior
except for the water content. The decomposition of the sample started
at 170 °C. The residue at 800 °C has also been identified as CuO with a
mass loss of 9.9% (Δωcalc = 9.7%).
In both preparations, the yield of the new compound varied from 70
to 80%. The compounds present solid state stability in air, and both are
soluble in dimethylsulfoxide and ethanol. The solid state molecular
structures were determined by X-ray diffraction analysis as
(SerH2)2[CuCl4]·½H2O (C34H37Cl8CuN2O0.5) for the crystals from the
refrigerator (hemi-hydrate form, yellow crystals) and as
(SerH2)2[CuCl4] (C34H36Cl8CuN2, yellow crystals) for the room tem-
perature crystals (un-hydrate form).
2.2.2. Single crystal X-ray diffraction data
The measurements were performed on an Oxford Xcalibur Gemini,
Eos CCD diffractometer with graphite-monochromated MoKα
(λ= 0.71073 Å) and CuKα (λ= 1.54178 Å) radiation for the hydrate
and un-hydrate, respectively. X-ray diffraction intensities were col-
lected (ω scans with ϑ and κ-offsets), integrated and scaled with
CrysAlisPro [26] suite of programs. The unit cell parameters were ob-
tained by least-squares refinement (based on the angular settings for all
collected reflections with intensities larger than seven times the stan-
dard deviation of measurement errors) using CrysAlisPro. Data were
corrected empirically for absorption employing the multi-scan method
implemented in CrysAlisPro. The structures were solved by direct
methods with SHELXS of the SHELX suit of programs [27] and the
corresponding molecular models developed by alternated cycles of
Fourier methods and full-matrix least-squares refinement with SHELXL
of the same package. The hydrogen atoms of all SerH2+ molecules were
positioned stereo-chemically and refined with the riding model. The
methyl H-positions were optimized by treating them as a rigid group
which was allowed to rotate during the refinement around the corre-
sponding NeC bonds such as to maximize the residual electron density
at the calculated positions. One water H-atom of (SerH)2[CuCl4]·½H2O
was located in a difference Fourier map and refined at its found position
with an isotropic displacement parameter. The other water H-atom
could not be located reliably and therefore it was not included in the
final molecular model. Crystal data, data collection procedure, struc-
ture determination methods and refinement results are summarized in
Table 1.
Crystallographic structural data have been deposited at the
Cambridge Crystallographic Data Centre (CCDC). Any request to the
CCDC for this material should quote the full literature citation and the
reference number CCDC 1519924 [(SerH)2[CuCl4]·½H2O] and CCDC
1519925 [(SerH)2[CuCl4]].
2.3. in vitro biological and pharmacological activities
2.3.1. Anti-thyroid activity
Iodine complexation was assayed following our reported methods,
based on Lang's method [17]. Experiments concerning lactoperoxidase
from bovine milk (LPO)-inhibition were performed as follows using
phosphate buffer (pH 7) at 25 °C. The spectroscopic data were collected
with a UV/Vis spectrophotometer and the assay of LPO enzyme activity
was followed by catalysis of ABTS oxidation monitoring the UV ab-
sorption at 411 nm. The enzyme activity, after the complex addition,
was expressed as a percentage of that observed in the absence of in-
hibitors. In a typical experiment, 100 mM ABTS and 30 mM hydrogen
peroxide solutions (from a 30% w/w solution) were freshly prepared in
deionized water. A solution of the lactoperoxidase enzyme
(0.15–0.25 unit mL−1) was prepared in cold deionized water and used
immediately for the assay. In a 1 mL reaction mixture, the final con-
centrations were 12.9 nM LPO, 28.7 mM H2O2, 1.4 mM ABTS, and
1–100 mM of the inhibitor [28].
2.4. Antioxidant properties
2.4.1. Superoxide dismutase assay (SOD)
The antioxidant properties were assayed following our reported
methods [29]. In this method, the system (PMS)/(NADH) produces the
superoxide anion radical. The system contains 0.5 mL of sample, 0.5 mL
of 1.40 mM NADH, and 0.5 mL of 300 μM NBT, in 0.05 M phosphate
buffer (pH 7.5). After incubation at 25 °C for 15 min, the reaction starts
by the addition of 0.5 mL of 120 μM PMS. The solutions of the complex
were prepared in DMSO before adding the phosphate buffer to obtain
the desired final concentrations. The final DMSO to buffer concentra-
tion ratio never exceeded 5:100. Then, the reaction mixture was in-
cubated for 5 min at 25 °C. For comparative purposes sertraline was
tested under the same experimental conditions. The results were de-
termined by monitoring the absorbance at 560 nm. The amount of
compound that produced a 50% inhibition of NBT reduction was ob-
tained from a plot of percentage of inhibition versus compound con-
centration. Kinetic constant value (k), which is independent of both
detector concentration and nature, was calculated according to:
kMcCF = kdetector x [detector]/IC50(compound), where kNBT (pH 7.8)
= 5.94 × 104 mol−1 L s−1 and [detector] = detector concentration.
2.4.2. 1,1-Diphenyl-2-picrylhydrazyl assay
The antiradical activity of the compounds was measured in tripli-
cate as follow: methanolic solution of DPPH% (4 mL, 40 ppm) was
added to 1 mL of the antioxidant solutions in 0.1 M Tris-HCl buffer
(pH 7.1) at 25 °C, giving a final concentration of 10 μM. After 60 min of
the reaction in the dark, the absorbance at 517 nm was measured and
compared with the absorbance of the control prepared in a similar way
without the addition of the compounds (this value was assigned arbi-
trarily as 100%).
2.5. Scavenging of the hydroxyl radical
Hydroxyl radicals were generated by the ascorbate-iron-H2O2
system. Briefly, the reaction mixture contained 3.75 mM 2-deoxyribose,
2.0 mM H2O2, 100 μM FeCl3, and 100 μM EDTA with or without the
tested compounds in 20 mM KH2PO4-KOH buffer, pH 7.4. The reaction
was triggered by the addition of 100 μM ascorbate and the mixture was
incubated at 37 °C for 30 min. Solutions of FeCl3, ascorbate, and H2O2
were made up in deaerated water immediately before use. The extent of
deoxyribose degradation by hydroxyl radical was measured with the
thiobarbituric acid method [12].
2.6. Peroxidase mimetic activity
The assay was performed according to the procedure published by
Feng et al. [30]. Sertraline and the copper complex were dissolved in
DMSO. The bromination reaction activity experiments were performed
at 25 ± 0.5 °C and pH 5.8 (buffer solution of NaH2PO4-Na2HPO4).
Reactions were initiated with the presence of phenol red solution
(20 μM), an aliquot of 30% H2O2, KBr 2 M and 7.38 μM of the copper
complex. The expected spectral data should optimally show the gradual
disappearance of the peak at 443 nm due to the loss of phenol red and
an increase in the absorbance of the peak at 592 nm due to the for-
mation of the bromophenol blue product. The spectra were recorded at
1 min intervals. The first-order character of the reaction is demon-
strated by the linearity of plot of ln([A]/[A0]) vs. time, where A and A0
are the absorbances at 592 nm, measured at times t and t= 0, re-
spectively. The rate constants derived from the pseudo-first order plot
on the concentrations vary linearly in the experimental conditions.
2.7. Antimicrobial assays
The antibacterial and antifungal profiles of the (SerH2)2[CuCl4]
have been studied against bacterial and fungal strains by the agar
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dilution method. Control strains included five bacterial strains:
Escherichia coli ATCC 35218, Pseudomonas aeruginosa ATCC 27853,
Staphylococcus aureus ATCC 25923, Staphylococcus epidermidis ATCC
1263 and Enterococcus faecalis ATCC 29212 and seven strains of
Candida namely: Candida parapsilosis ATCC 22019, Candida albicans
ATCC 10231, and clinical isolates of Candida tropicalis, Candida krusei,
Candida glabrata, Candida parapsilosis and Candida albicans. Mueller
Hinton Broth (MHB) or Mueller Hinton Agar (MHA) has been used for
the cultivation/assay medium for all strains. The inocula of bacterial
and fungal strains were prepared from 18 h-old broth cultures. A
McFarland 0.5 suspension was prepared for each isolate (~108 colony
forming units (CFU) per mL, CFU mL−1). The fungal suspension
(~108 CFU mL−1) was directly inoculated onto the agar surface,
whereas the bacterial suspension was 1:10 diluted prior to inoculation
(~107 CFU mL−1). The minimum inhibitory concentration (MIC) was
determined by the agar dilution method. The compounds were dis-
solved in 50% aqueous dimethylsulfoxide (DMSO) solution to a final
concentration of 15 mg mL−1. Serial two-fold water dilutions were
prepared from the stock solution of the antimicrobial agents to give
concentrations ranging from 14.65 to 15,000 μg mL−1. All solutions
were sterilized by filtration before use. Then, 0.5 mL of each dilution of
antimicrobial solution were added to 4.5 mL of melted MHA and
poured into a square (45 × 15 mm) plate. The final concentrations
ranging in the MHA were from 1.46 to 1500 μg mL−1. An agar plate
without antibacterial agent was established as a sterility and organism
growth controls. The plates were prepared and used on the same day.
After cooling and drying, the plates were inoculated with each micro-
bial suspension. The inoculum of 2 μL of the germ suspensions were
streaked onto the plates and incubated aerobically at 37° for 24 h and
48 h for bacteria and fungi, respectively. Each MIC experiment was
repeated three times. Inhibition of microbial growth in the plates
containing tested solutions was judged by comparison with growth in
control plates. The MIC was defined as the lowest dilution of the
complex that inhibited the visible growth of the tested organism. A
single colony or a faint haze caused by the inoculum was considered to
be no growth [10].
2.8. In vivo pharmacological screening
The prepared compound was evaluated for their in vivo anti-
depressant and analgesic activities by the Forced Swimming test (FST)
and the hot plate method in Wistar rats, respectively.
2.9. Animals
Experiments were carried out on male Wistar rats weighing
170–290 g. The animals were maintained on a 12 hour light
(08:00–20:00 h)-12 hour dark cycle, with free access to food and water,
except during testing. Under these conditions, abundant evidence seems
to rule out possible interference with experimental data [[31].].
Rats were housed in groups of four, in individual polyethylene cages
(55 × 38 × 30 cm). Their weights were recorded at the beginning and
end of each experiment. Animals were used only in one experiment.
All studies described were conducted in accordance with the Guide
for Care and Use of Laboratory Animals provided by the National
Institutes of Health, USA and AVMA Guidelines for the Euthanasia of
Animals, 2013 Ed. The experiments were performed after approval of
the protocol by the Ethics Committee for the care and use of Laboratory
Animals of the Universidad Nacional de La Rioja, Argentina.
2.10. Antidepressant activity
2.10.1. Drugs and treatment
For (SerH2)2[CuCl4] the experimental doses of 13.30 and 26.6 mg/
kg and a therapeutic dose of 10.00 mg/kg and a higher dose of
20.0 mg/kg of sertraline have been selected. The doses of the copper
Table 1
Crystal data and structure refinement results for the (SerH2)2[CuCl4] salts.
Hydrate Un-hydrate
Empirical formula C34 H37 Cl8 Cu N2 O0.5 C34 H36 Cl8 Cu N2
Formula weight 828.79 819.79
Temperature (K) 297 (2) 297 (2)
Wavelength (Å) 0.71073 1.54184
Crystal system Monoclinic Monoclinic
Space group P21 P21
Unit cell dimensions
a (Å) 8.0807 (2) 13.8727 (6)
b (Å) 36.2781 (8) 7.5090 (3)
c (Å) 12.6576 (3) 18.618 (1)
β (°) 95.665 (2) 104.563 (6)
Volume (Å3) 3692.5 (2) 1877.1 (2)
Z, density (calcu., Mg/m3) 4, 1.491 2, 1.450
Absorption coefficient (mm−1) 1.200 6.267
F (000) 1696 838
Crystal shape/color Plate/yellow Plate/yellow
Crystal size (mm3) 0.375 × 0.176 × 0.051 0.237 × 0.083 × 0.037
ϑ-range (°) for data collection 2.868 to 27.000 3.291 to 72.396
Index ranges −9≤ h≤ 10, −43≤ k≤ 45, −16≤ l≤ 16 −17≤ h≤ 16, −9≤ k≤ 5, −22≤ l≤ 22
Reflections collected 22,045 8261
Independent reflections 13,434 [R (int) = 0.0292] 4754 [R (int) = 0.0612]
Observed reflections [I > 2σ (I)] 11,104 3244
Completeness (%) to ϑ= 25.24° 99.8 99.9
Absorption correction Semi-empirical from equivalents Semi-empirical from equivalents
Refinement method Full-matrix least-squares on F2 Full-matrix least-squares on F2
Data/restraints/parameters 13,434/2/828 4754/1/408
Goodness-of-fit on F2 1.021 1.025
Final R indicesa [I > 2σ (I)] R1 = 0.0392, wR2 = 0.0746 R1 = 0.0719, wR2 = 0.1714
R indices (all data) R1 = 0.0536, wR2 = 0.0808 R1 = 0.1047, wR2 = 0.1996
Absolute structure parameter −0.003(7) 0.03(4)
Larg. diff. peak and hole (e·Å−3) 0.317 and −0.303 1.272 and −0.456
a R1 = Σ||Fo|− |Fc|| / Σ|Fo|, wR2 = [Σw (|Fo|2− |Fc|2)2 / Σw (|Fo| 2)2]1/2.
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salts were proportionally equivalent to those of sertraline. Higher doses
have also been selected to evaluate its dose-response activity.
Rats were treated with the saline solution (rats control) or CuCl2,
sertraline hydrochloride and (SerH2)2[CuCl4] once a day and all solu-
tions were administered by oral route in a constant volume of 10 mL/kg
body weight. The rats were randomly distributed into five groups which
were subjected to the following treatments: Group 1: saline (control
group), Group 2: CuCl2 (2.70 mg/kg), Group 3: CuCl2 (5.40 mg/kg),
Group 4. sertraline hydrochloride (10.0 mg/kg), Group 5. sertraline
hydrochloride (20.0 mg/kg), Group 6: (SerH2)2[CuCl4] (13.30 mg/kg)
and Group 7: (SerH2)2[CuCl4] (26.6 mg/kg). Saline solution and com-
pounds were administered orally by gavage (p.o.) for 14 days.
Statistical analysis was carried out by one-way ANOVA followed by
Bonferroni's test.
2.11. Forced swimming test (FST)
The forced swimming test (FST) is a well-accepted procedure to
quantify the antidepressant-like action of drugs [32] and to assay
through rat treatments the antidepressant efficacy in humans [33].
Stress is a well-known risk factor in the development of depression. The
FST employs forced swimming stimuli as stressor to generate a behavior
characterized by increased immobility time.
Swimming sessions were conducted by placing rats in individual
Plexiglas cylinders (46 cm tall × 20 cm in diameter), filled with water
(23–25 °C) up to 30 cm from bottom. All swimming sessions were car-
ried out between 12:00 and 18:00 h.
In the protocol, two sessions were conducted: an initial 15 min pre-
test on day 1 followed by a 5 min test on day 15. Drug treatments began
on day 1 after the pre-test session and it was administered from day 1 to
14 [34]. At the end of both swimming sessions, rats were removed from
the cylinders, dried with towels, placed in heated cages for 15 min,
allowed to rest and recover, and then returned to their home cages. The
cylinders were emptied and cleaned between rat tests. Each animal was
assigned randomly to a treatment, and was only employed for one pre-
test/test session.
2.12. Analgesic activity-hot plate test
The hot plate consisted of an electrically heated surface (Socrel DS-
35, Ugo Basile, Comerio, VA, Italy) kept at a constant temperature of
54 ± 0.8 °C. In the test, the rats were kept inside a circular transparent
plastic cage on the hot plate. The time taken for the rats to respond to
the thermal stimulus (licking paws or jumping surface) was recorded as
the response latency (in second). If the animals did not respond within
45 s (cut-off time), they were removed from the plate to avoid tissue
damage [35]. Animals were distributed in 4 groups: Group 1: saline
solution (0.4% NaCl) (control), Group 2: sertraline (SerH2Cl) (10 mg/
Kg), Group 3: CuCl2 (2.7 mg/Kg) and Group 4: (SerH2)2 [CuCl4]
(13.30 mg/kg). Saline solution and compounds were administered or-
ally by gavage (p.o.) for 14 days. The antinociceptive activity of
(SerH2)2[CuCl4], CuCl2 and sertraline, after acute and chronic admin-
istration (for 14 days), was evaluated using hot plate method. Statistical
analysis was carried out by one-way ANOVA followed by Dunnett's test.
In acute experiments, rats were administered 60 min prior to hot plate
test or open field test and in chronic experiments 24 h after the last dose
administration.
2.13. Behavioral scoring
For behavioral sampling, rats were rated at 5 s intervals throughout
the duration of the forced swimming session. At each 5 s interval, the
predominant behavior was assigned to one of three categories: (1)
immobility: floating in the water without struggling, and making only
those movements necessary to keep the head above the water; (2)
swimming: making active swimming motions, more than necessary to
merely keep the head above water (i.e., moving around in the cylinder);
and (3) climbing: making active movements with forepaws in and out of
the water, usually directed against the walls. Scores for each behavior
were expressed as total behavioral counts per 5-min session [32].
2.14. Open field test
This test was carried out to determine whether different treatments
that were effective in the hot plate test or forced swimming test had
non-specific effects because the locomotor activity may influence im-
mobility in the forced swim test [36] or in the latency response in the
hot plate test [37].
The apparatus used consisted of a black, square open field (60 cm by
60 cm) with the floor divided in squares (15 × 15 cm) by means of
white lines. The open field was placed in a quiet room only illuminated
with a 75 W electric bulb hung 75 cm above it. Testing was performed
between 14:00 and 17:00 h.
Each animal was placed in the centre of the open-field arena and the
locomotor activity was expressed as the number of floor units the an-
imal entered with all of its limbs over a period of 5 min. (ambulatory
counts). After each animal was removed, the open field was carefully
cleaned with a damp cloth.
The locomotor activity in rats was evaluated 10 min previously
exposed to the forced swimming test or hot plate test. The behavior was
scored by an observer who was unaware of the experimental procedures
previously performed on the animals and the results were expressed as
mean ± S.E.M.
2.15. Albumin interaction
Bovine serum albumin (BSA) was dissolved in 0.1 M Tris-HCl buffer
(pH 7.4) to attain a final concentration of 6 μM. Sertralonium tetra-
chlorocuprate(II) solution was added drop-wise to the above 6 μM BSA
preparation to ensure the formation of a homogeneous solution and to
obtain the desired concentration of 0–100 μM. Adequate solubility was
reached under these experimental conditions and the compounds did
not showed significant fluorescence that could interfere with the mea-
surements. For each sample and concentration, three independent re-
plicates were performed at 25 °C and 37 °C. BSA 6 μM was titrated by
successive additions of complex solutions from 0 to 100 μM and the
fluorescence intensity was measured (excitation at 280 nm and emis-
sion at 348 nm). All the fluorescence quenching data were analyzed
according to previous studies performed in the laboratory by applying a
traditional mathematical procedure. The fluorescence-quenching me-
chanism has been analyzed using the Stern-Volmer Eq. (1) [38,39]..
= +F F 1 K [Q]0 sv (1)
where F0 is the steady-state fluorescence intensity of BSA alone
while F is the observed intensity upon increasing the quencher con-
centration, Ksv is the Stern-Volmer quenching constant and [Q] is the
quencher concentration. Usually, the curve of F0/F vs. [Q] is linear if
the type of quenching involves a unique process: static or dynamic.
Static quenching is due to the complex formation between the fluor-
ophore and the quencher. It can be distinguished from collision effects
because generally the Ksv value is higher than the value of the dynamic
quenching constant (Kq). Considering that Kq = Ksv/τ0 (where
τ0 = 10−8 s is the average lifetime of the biomolecule without
quencher), this constant can be estimated and compared with the
maximum diffusion collision quenching rate constant (reference value
from the literature) which is 2 × 10−10 M−1 s−1 [38,39]. If the Ksv
value is greater, then a mechanism of interaction through the complex
formation can be proposed. Otherwise it would be a collisional
quenching. If the quenching is static, it is assumed that there are spe-
cific binding sites. These binding sites, and their association constants,
were estimated using the following mathematical relationship:
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− = +log [(F F) F)] log K n log [Q]0 b (2)
where Kb is the binding constant and n is the average number of
biding site per protein molecule.
To obtain information about the type of interaction, the thermo-
dynamic parameters were calculated using Van't Hoff equation [38,39]:
= −ln (K K ) ΔH R (1 T –1 T)b2 b1 0 2 1 (3)
where T1 and T2 are the absolute temperatures at which Kb1 and Kb2
were determined. The standard free energy change (ΔG0) and the
standard free entropy change (ΔS0) were evaluated according to the
well known thermodynamic relationships:
= −ΔG RT ln K0 b (4)
= −ΔS (ΔH ΔG ) T,0 0 0 (5)
3. Results and discussion
3.1. Crystallographic structural results
The crystal asymmetric unit of the un-hydrate hosts a single
(SerH2)2[CuCl4]·½H2O molecule while the hemi-hydrate contains two
different molecules which share a single crystallization water molecule.
In what follows, we shall discuss mainly the molecular structure of the
better refined hydrated salt.
Fig. 1 shows an ORTEP [40] drawing of (SerH2)2[CuCl4]·½H2O and
the corresponding intra-molecular bond distances and angles of this and
the un-hydrate salts are respectively given in Tables S1a and S1b. All
pharmaceutical sertraline (SerH2+) molecules in both solid forms are
found in the cationic moiety, protonated at its amine group, namely
(1S,4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydro naph-
thalen-1-amine (for short, SerH2+).
Because of extended molecular orbital π-delocalization the phenyl
and dichlorophenyl groups of SerH2+ are planar [rms deviation of non-
H atoms from the best least-square plane< 0.010 Å for phenyl rings
and< 0.031 Å for dichlorophenyl groups]. Phenyl and dichlorophenyl
planes, in turn, subtend dihedral angles of 87.9(1)° (SerH #1), 81.3(1)°
(SerH #2), 68.8(1)° (SerH #3), and 86.5(1)° (SerH #4).
Intra-molecular bond distances and angles within the SerH2+ mo-
lecules in both salts agree with each other and with corresponding
values reported for the related (SerH2)2[ZnCl4] salt [11], sertraline
hydrochloride polymorphs [41,42], for other SerH2+ salts [43,44]. and
for the sertraline coumarin 3-carboxylate [10].
The four independent SerH2+ molecules in (SerH2)2[CuCl4]·½H2O
can be grouped in two sets, (#1, #3) and (#2, #4), with the molecules
in each set having the same boat-like conformation of naphathalene
rings. Besides this, the conformations of the SerH2+ molecules differ
significantly from each other and from the ones of the other related
A 
B
Fig. 1. Drawing of (A) (SerH2)2[CuCl4]·½H2O and (B)
(SerH2)2[CuCl4] showing the labeling of the non-H atoms and their
displacement ellipsoids at the 30% probability level. For clarity, only a
few representative atoms have been identified in the hydrate to show
the numbering scheme.
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compounds. This can be traced to relatively unhindered rotational
freedom of SerH2+ around the CeC σ-bond linking the dichlorophenyl
and the naphthalene rings and also around the C(naph)eN σ-bond.
As expected, the mayor differences in bond lengths of SerH2+ mo-
lecules as compared with neutral sertraline [45], show up as a length-
ening of C(naph)-N (of 0.045(8) Å in average) and in less degree of N-
CH3 (average of 0.022(8) Å) bond distances upon attachment of the
proton to the amine groups.
Copper-chloride distances in the [CuCl4]2− counter-ions are in the
range from 2.204(2) to 2.288(1) Å. Consistent with the tendency of Cu
(II) ion to form square planar complexes, [CuCl4]2− shows a highly
squashed tetrahedral (along the C2 axis) conformation with trans (Cl-
Cu-Cl) angles in the range from 125.36(6) to 141.23(7)° and cis (Cl-Cu-
Cl) angles in the 93.85(6)–103.90(6)° range. This contrasts with the
[ZnCl4]2− counter-ions in the related (SerH)2[ZnCl4] salt where the Zn
(II) complex is much closer to a perfect tetrahedron [Zn-Cl bond dis-
tances in the 2.251(2)–2.282(2) Å range and Cl-Zn-Cl angles in the
range from 105.69(7) to 114.76(7)°] [11].
The crystalline (SerH2)2[CuCl4]·½H2O salt is further stabilized by a
complex net of intermolecular H-bonds involving the SerH2+
amide> NH2+ as the donor group and as acceptors the water molecule
[d(N…O) = 2.798 Å, ∠(NeH…Ow) = 163.9°] and the chlorine atoms
of neighboring [CuCl4]2− complex ions [N…Cl distances in the
3.174–3.564 Å range and NeH…Cl bond angles in the 119.5–171.9°
range] and also by a OweH…Cl bond [d(Ow…Cl) = 3.226 Å,
∠(OweH…Cl) = 151.5°]. The H-bonding structure for both salts is
further detailed in the supplementary Tables S6a and S6b.
3.2. Synthesis and physicochemical characterization
As mentioned above, different solid state structures were obtained
depending on the crystallization temperature. Room temperature fa-
vored the formation of the un-hydrate form while the solution pre-
served at 2–5 °C led to a hydrate crystal form. Characterization was
performed using Infrared, Raman, UV–vis and EPR spectroscopies and
magnetic measurements.
Both complexes showed similar FTIR spectra (Fig. S1). The most
remarkable changes are produced in the NH2+ vibrational modes re-
gion (red shift) [11] coming from the hydrogen N+HeX bonding af-
fects (in the hemi-hydrate salt at 2457 cm−1 (νas) at 2371 cm−1 (νs)
and in the un-hydrate salt at 2450 cm−1 (νas) and 2368 cm−1 (νs),
respectively). The ν(CeN) stretching mode appears at 1029 cm−1 and
the CeH in-plane bending frequencies, the CeH out-of-plane bending
and the skeletal vibrations were observed in the expected ranges [11].
Complementary Raman measurements afforded us to assign to the
ν(CeCl) stretching mode the peaks found at 481 cm−1 (FTIR) and
483 cm−1 (Raman) and assign two of the expected Cu-Cl modes the
Raman lines located at 306 and 240 cm−1 (Fig. S2) together with the
positive assignment of the absorption of the bending water mode in the
hydrate form (1620 cm−1 in the FTIR spectrum) which became barely
visible in Raman spectrum. For both complexes, reflectance spectra
showed the expected d-d band transition of [CuCl4]2− ion (> 850 nm,
2B2→ 2A1 transition) and the typical three bands corresponding to
charge-transfer transitions located at 401, 282 and 234 nm (Fig. S3A)
[23,46].
The X- and Q-band electron paramagnetic resonance (EPR) spec-
trum of (SerH2)2[CuCl4].½H2O is shown in Fig. 2. No hyperfine struc-
ture or further splitting of the signals was observed [23]. The g-tensor
parameters (g‖ = gz = 2.410 and gx = gy = g⊥= 2.120, giso = 2.217)
(Fig. 2C) were resolved with g-values in concordance with the presence
of tetrachlorocuprate after the Jahn-Teller dynamic effect has been
stabilized.
To study the magnetic behavior of the hydrate sample, the EPR (X-
band) spectrum in the range 290–5K was measured. The room tem-
perature EPR signal showed a line-shape typical of isotropic ligand field
(Fig. 2A). However, as the temperature decreases, the EPR line narrows
and, as a result, the peak intensity increases (Fig. 2B, X-band, 10K). This
change in the EPR spectra at low temperature suggests a decrease in the
strength of the Jahn-Teller effect. The g-tensor parameters (obtained
from a simulation of this EPR spectrum) were in accord with a rhombic-
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Fig. 2. (A) Temperature dependence of the electron paramagnetic resonance (EPR)
spectrum measured at X-band of (SerH2)2[CuCl4]·½H2O complex from 290 K to 5 K.
(B) Experimental (solid line) and calculated (dashed line) powder electron paramagnetic
resonance (EPR) spectrum of the (SerH2)2[CuCl4]·½H2O complex measured at X-band
(290 K, 9.39 GHz).
(C) Experimental (solid line) and calculated (dashed line) powder electron paramagnetic
resonance (EPR) spectrum of the (SerH2)2[CuCl4]·½H2O complex measured at Q-band
(290 K, 33.9 GHz).
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like type of signal, namely gz = 2.265, gx = 2.075, gy = 2.190
(giso = 2.176). To understand the changes, variable-temperature mag-
netic susceptibility measurements were carried out in the 5–300 K
temperature range on a powdered sample of the complex. The thermal
variation of the inverse of the magnetic molar susceptibility (χm−1) and
the χmT product (χmT= (μeff)2/8) are shown in Fig. 3. It can be ap-
preciated that the χmT magnitude remains practically constant down to
20 K, temperature below which the value of the effective magnetic
moment rapidly drops to zero. At room temperature, the χmT value is
0.885 cm3·K·mol−1 which are close to the expected value for two un-
coupled copper (II) ions with g= 2.18, in agreement with the EPR
results. On the other hand, the Curie-Weiss law
= +χ C (T θ)m m (6)
describes the whole measured temperature range. The calculated
values of Cm and the Weiss temperature (θ) are 0.89 cm3·K·mol−1 and
1.7 K, respectively. This latter temperature is indicative of weak anti-
ferromagnetic super-exchange coupling between the unpaired electrons
on neighboring [CuCl4]2− ions in the lattice. A more complete de-
scription of the observed magnetic behavior can be obtained using the
Bleaney-Bowers equation for copper dimers [47], derived from the
Heisenberg spin Hamiltonian (H=−2JS1S2) for two coupled S = 1/2
ions:
= + −
−χ (2Ng β kT)[3 exp.( 2 J kT)]m 2 2 1 (7)
where N is the Avogadro's number, β the Bohr magneton and k the
Boltzmann constant. From the best least-squares fit of Eq. (2) (solid line
in Fig. 3) to the susceptibility data, there results an exchange parameter
J/k =−2.5 K and a gyromagnetic g-value of 2.17, being the reliability
R-factor (defined as R = Σ[χmTexp− χmTcal]2 / Σ[χmTexp]2), equal to
1·1e−5. The good agreement between experimental and calculated data
confirms the predominance of dimeric super-exchange interactions
between neighboring [CuCl4]2− ions in the lattice, even if extensive
exchange must be operative as indicated by the collapse of the hy-
perfine structure. The observed smallness of the J-value is due to weak
super-exchange paths linking neighboring Cu(II) ions. In fact, these
paths involve long intermolecular CuCl…ClCu and Cu…ClCu distances
in the lattice [larger than 4.01 and 4.74 Å, respectively] and also un-
favorably oriented magnetic molecular orbitals.
The un-hydrate form does not present any outstanding character-
istics beyond that published in the literature.
3.3. Solution characterization and stability
Because of the similarity of the two compounds, solution char-
acterization, biological, and pharmacological studies were performed
only on (SerH2)2[CuCl4] complex. Conductivity measurement of 1 mM
solution of the complex in DMSO was carried out at 25 °C. The molar
conductivity of the solution remains constant
(ΛM= 62 Ω−1·cm2·mol−1) from 1 to 2 h. The conductivity value in-
dicates a 1:2 electrolyte nature of the complex and is consistent with
those values found for similar, 1:2 metal complexes in DMSO [48]. The
new compound is therefore a 1:2 electrolyte and exists as SerH2+ and
[CuCl4]2− ions.
The UV–vis solution spectrum of the complex (DMSO, 0.001 M)
showed three CT transition bands similar to that found in the solid,
located at 258 nm (ε= 567.5 M−1·cm−1), 340 nm (930 M−1·cm−1)
and ~422 nm (shoulder) (Fig. S4A) [23]. At lower energy, the spec-
trum showed a broad band in the 600–1100 nm range (Fig. S4B). The
pattern of the spectra observed is the one expected for tetra-
chlorocuprate complexes. The stability of this solution was followed by
UV–vis spectroscopy. It was found that after 1 h of solution preparation,
there were no significant spectral changes (Fig. S4A), hence indicating
together with the conductivity measurements that during the manip-
ulation time for biological assays (15 min) the complex remains stable.
By EPR spectroscopy this assumption has also been confirmed (Fig.
S4B). The spectrum of a DMSO solution of the new compound showed
only one resonance line assuming the presence of one monomeric so-
lution species. The simulation predicted that this signal is originated by
a Cu(II)-chromophore with the spin Hamiltonian parameters of
giso = 2.175 and the hyperfine coupling constant of
Aiso = 33 × 10−4 cm−1 in agreement with the expected one for
CuCl4−2 species [23].
3.4. In vitro evaluation of potential biological-pharmacological activities
3.4.1. Antimicrobial activity
Considering the relevance that Cu(II) complexation and the ni-
trogen-containing heterocyclic compounds have in the pharmacological
profile of antimicrobial activities [49], and taking into consideration
the involvement of P. aeruginosa, E. coli and S. aureus in the develop-
ment of agranulocytosis (rare complication produced by antithyroid
drugs) [50], the effect of the here studied compounds on fungal and
bacterial strains were also evaluated. The ability of the complex to in-
hibit the growth of fungal and bacterial strains was investigated em-
ploying the minimum inhibitory concentration (MIC) assay (Table 2).
Antibacterial activity can be quantified as follow: significant results
when the MIC values are of 100 μg mL−1 or less; moderate activity
when the MIC values are in the 100–500 μg mL−1 range; and lack of
activity when MIC values are higher than 1000 μg mL−1. It can be seen
that the complex exhibits strong activity except against P. aeruginosa.
Since these activities are similar to the ones showed by sertraline alone,
we conclude that the antibacterial properties are most likely due the
presence of this pharmaceutical in the complex and no relevant sy-
nergistic effect was observed related to the presence of copper.
However, it can be noted that a probable administration of the complex
will not affect the antimicrobial activity of sertraline.
Fig. 3. Magnetic susceptibility of (SerH2)2[CuCl4]·½H2O in the temperature range from 5
to 290 K.
Table 2
Minimum inhibitory concentrations (MICs) of SerH2Cl (sertraline), CuCl2 and
(SerH2)2[CuCl4] for bacterial and fungal strains. MIC values in μg mL−1.
SerH2Cl CuCl2·2H2O (SerH2)2[CuCl4]
E. coli 24 375 48
P. aeruginosa 750 375 1500
E. faecalis 24 375 24
S. aureus 24 375 48
S. epidermidis 24 375 24
C. albicans 6 > 1500 12
C. albicans ATCC 10231 12 > 1500 12
C. parapsilosis 12 > 1500 6
C. parapsilosis ATCC 22019 6 > 1500 6
C. krusei 3 1500 6
C. glabrata 3 1500 6
C. tropicalis 6 > 1500 6
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3.4.2. Anti-thyroid activity
It is well known that an uncontrolled overproduction of thyroid
hormones is the reason for a disease condition called “hyperthyr-
oidism”. In a proposed mechanism of action, first the thyroid perox-
idase (TPO) heme-containing glycoprotein leads via endogenous-pro-
duced hydrogen peroxide to the generation of an oxidized form of the
enzyme (Scheme,(A)). Then, the oxidized form reacts with iodide to
form an iodine-intermediate which in turn reacts with specific tyrosine
residues in the thyroglobulin (Tg) to form monoiodotyrosine and diio-
dotyrosine. Finally, successive intra-molecular coupling of MIT and DIT
forms triiodothyronine and the coupling of two DIT molecules affords L-
tri-iodo-thyronine (T3) and L-tetra-iodothyronine or thyroxine (T4)
formation. (Scheme, (B)).
The overproduction of T4 and T3 can be controlled by anti-thyroid
drugs which efficiently can act in two ways, namely (i) forming charge-
transfer complexes with molecular iodine in the thyroid gland hence
avoiding the access of the iodine to the thyroglobulin, or (ii) inhibiting
thyroid peroxidase (TPO) and blocking the thyroid hormone synthesis.
Based in those possibilities, the ability of the complex to form charge
transfer-iodine complex and to inhibit LPO has been evaluated. Due to
the fact that sertraline hydrochloride-iodine interaction was previously
shown to lead to charge-transfer complex with iodine [17], its effect on
LPO was only assessed in this work.
The complexation of the compounds with iodine provided evidence
to its possible anti-thyroid effects. Previous work showed that sertraline
hydrochloride in presence of iodine led immediately to the appearance
of a new CT band located at 257 nm. This band has a Kc value of
3277.48 L mol−1 that indicates strong activity (much larger than the
100 L mol−1 reference value) [17]. In this work, sequential addition of
increasing concentrations of (SerH2)2[CuCl4] complex on iodine solu-
tion produced a reduction of the iodine band intensity but no CT band
was observed. This behavior suggests that the compound has no ability
to trap iodine but may act as a catalyst promoting the disappearance of
iodine.
Besides the capacity of several substances containing free N-H
moiety to form CT complexes with iodine, it has also been proposed
that these types of compounds can act as TPO inhibitors. Researchers
suggested a possible competitive coordination with the iron center of
the enzyme, which is mediated by hydrogen bonding formation through
N-H group [51]. When sertraline hydrochloride was tested on LPO as a
model for TPO, inhibition behavior was observed in a dose-dependent
manner (Fig. 4). The calculated IC50 = 80 μM resulted lower than the
reported value for other typical antidepressants. It is worth mentioning
that for the others antidepressants (desipramine, imipramine, and clo-
mipramine among others) horseradish peroxidase [52] was used to
perform the experiments. For this reason, direct comparison was not
possible to achieve. However, in the cases in which the IC50 values were
determined, they ranged between 3.7 and 0.81 mM. It may be noted
that sertraline behaves as a dual inhibitor, capturing iodine and in-
hibiting the enzyme from being a good anti-thyroid agent. On the other
hand, the copper complex did not show any significant LPO inhibition,
hence indicating that the LPO inhibitory activity of sertraline is lost
upon salt formation.
3.4.3. Catalytic activity
As mentioned above, previous findings showed characteristic
catalytic activity of tetrahalocuprate salts [23,24]. Furthermore, some
polymer-anchored copper complex was found to be very selective for
the oxidation of ethylbenzene to acetophenone [53]. Other relevant
aspect is their use as pharmaceutically acceptable salts for controlling
helminths and to improve growth in animals [54]. Based on this in-
formation and in the experimental observations mentioned above, it
was considered to test the catalytic activity of this complex in bromi-
nation reactions simulating haloperoxidases action. Metal complexes
are well-recognized models for V-haloperoxidases, especially vanadium
complexes [[55].].
The mimicking peroxidase activity was evaluated according to the
method proposed by Feng et al. [30] In this method, the effect of the
complex on the bromination of phenol red (the organic substrate) is
followed. The addition of a tetrachlorocuprate complex solution to the
standard reaction of bromide (phosphate buffer pH = 5.8) containing
phenol red produced a change in the color of the solution from yellow
to blue. This was observed in the electronic UV–vis spectra as an in-
crement of the 592 nm band intensity, characteristic for the bromo-
phenol blue product, and a corresponding decrease of the 443 nm band
intensity, due to the loss of the phenol red (Fig. 5). At first, the effect of
catalyst's amount was evaluated by taking different concentrations but
the reactions turned out to be too fast. For that reason, a lower amount
of catalyst (0.007 g) was employed and the reaction conditions opti-
mized.
For a better understanding, the bromoperoxidase mimetic activity
was evaluated considering a pseudo first-order reaction. The first-order
dependency on the organic substrate is demonstrated by the observed
linearity of ln([A]/[A0]) vs. time plots (Fig. S5), where A and A0 are the
absorbances at 592 nm, measured at times t and t= 0, respectively.
Average k and t1/2 values (0.157 ± 0.007 min−1 and 4.41 min, re-
spectively) have been obtained from different sets of experiments
confirming that the complex behaved as a bromoperoxidase-mimic
compound. Peroxidase mimic action could be associated to a me-
chanism of antithyroid action. It consists in a indirect inhibition of the
LPO enzyme. The compound does not inhibit the enzyme directly, but
reduce the H2O2 substrate generated by thyroid oxidase enzyme
avoiding the oxidation of the iron center of the LPO [31].
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Scheme. Schematic representation of the formation of L-
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Fig. 4. Inhibition curve of sertraline on LPO-catalyzed oxidation of ABTS.
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3.4.4. Antioxidant properties
As it was mentioned [19,20], there are several evidences indicating
a potential link between antidepressant and hyperthyroidism disease
and oxidative stress. For that reason, SOD mimetic activity of sertraline
and sertraline copper derived compound was also assessed. This de-
termination was performed with the idea that the tested compound
possible has more than one biological effect and that it could potentially
act also as antioxidant. Under our experimental conditions, sertraline
did not show any scavenging capacity. In Fig. 6 the antioxidant ability
of (SerH2)2[CuCl4] complex can be appreciated. The prepared complex
showed an IC50 value of 6.6 × 10−6 M and a resulting kMcCF value of
2.83 × 106 mol−1·L·s−1. Even though it was not as effective as the
enzyme (bovine erythrocyte SOD, IC50 = 2.1 × 10−7 M,
kMcCF = 8.5 × 108 mol−1·L·s−1) [29], experimental IC50 values below
20 × 10−6 M are still considered as strong SOD mimics. Thus, we
conclude that the tested complex do in fact exhibits catalytic activity
toward the dismutation of superoxide anions. This could be explained
bearing in mind that SOD activity depends strongly on the geometry
around the copper ion, being more effective in structurally flexible
geometry. This can be related to the ability of the ligand to accom-
modate the reduced copper(I) in a tetrahedral-like or linear environ-
ment. Considering the well-known structural variability of tetra-
halocuprates that can adopt square planar, distorted square planar, and
tetrahedral geometries [6], it can be suggested that (SerH2)2[CuCl4]
complex has the ability to show geometrical changes [23]. This is an
essential characteristic for the catalysis to take place as it is the geo-
metry of copper in the SOD enzyme that changes its distorted square
pyramidal environment.
On the other hand, the complex did not display antioxidant activ-
ities against other tested radicals (DPPH% and OH%) (data not shown).
3.5. In vivo assessment of potential pharmacological activities
3.5.1. Antidepressant activity
The role of copper in the affective disorders has not been well es-
tablished but there are some information related to its involvement in
mood disorders [56]. It was suggested that, as an enzyme component
(monoamine oxidase (MAO), dopamine b-hydroxylase (DBH), and tyr-
osine hydroxylase) it exerts influence in the pathophysiology of de-
pression [14] and participate in some disturbances in glutamatergic
transmission which are the base of glutamate hypothesis of depression
[56]. Several studies were performed on copper level in depressed
humans and some of them showed significantly reduced serum copper
level. Literature data prompted us to research about the efficiency of
copper salt as an antidepressant agent. In particular, we evaluate if this
bioelement may produce a synergistic effect in the sertraline anti-
depressant activity as an anionic component of this new compound.
Behavioral effects produced in the forced swimming test by ad-
ministration of sertraline, CuCl2 and (SerH2)2[CuCl4] are shown in
Fig. 7.
In accordance with our previous study [10,11] a 14-day treatment
with antidepressant sertraline (10.0 mg/kg, p.o.) significantly de-
creased immobility, concomitant with an increase in swimming without
modifying the climbing behavior, hence indicating an antidepressant
effect (Fig. 7). On the contrary, 20 mg/kg doses of sertraline failed to
alter FST behaviors.
The treatment with CuCl2 at the two-different doses dose failed to
modify the immobility, swimming and the climbing behavior compared
with saline controls.
Contrary to what it is observed for copper simple salt and sertraline,
the (SerH2)2[CuCl4] complex showed dose-dependent antidepressant
effect during the forced swimming test (FST) when compared with
saline controls (Fig. 7). The compound produced a dose-dependent
decrease in immobility and a corresponding increase in swimming
without significantly affecting the frequency of climbing time. The re-
sultant action mechanism is suggested to be similar to that of sertraline,
namely a typical serotonin-selective reuptake inhibitors (SSRIs class),
having in this case a more robust effect. Discarding the re-storing of
(A) 
(B) 
wavelength (nm)
450500550600
A
bs
or
ba
nc
e
0.00
0.05
0.10
0.15
0.20
0.25
0.30
592
443
t (min)
2 3 4 5 6 7 8 9 10 11 12 13 14 15
ln
 ([
A
]/[
A
0]
)
-0.5
0.0
0.5
1.0
1.5
2.0
2.5
Fig. 5. Oxidative bromination of phenol red catalyzed by the copper complex
(0.04 mmol). Spectral changes at 1 min intervals. Spectral data taken of aliquots in
pH = 5.8 (aqueous phosphate buffer), [KBr] = 2 M, [phenol red] = 20 μM,
(SerH2)2[CuCl4] = 7.38 μM.
-log [M]
3 4 5 6 7 8
%
 
In
hi
bi
tio
n 
of
 N
BT
 r
ed
uc
tio
n
0
10
20
30
40
50
60
70
80
90
100
Fig. 6. Effects of (SerH2)2[CuCl4] on the reduction of nitroblue tetrazolium by none-
nzymatically-generated superoxide (phenazine methosulfate and reduced nicotinamide
adenine dinucleotide system). The values are expressed as the mean ± SEM of at least
three independent experiments.
N. Martini et al. Journal of Inorganic Biochemistry 174 (2017) 76–89
85
copper levels because CuCl2 showed no significant effect, it can be
speculated that the synergistic behavior due to the copper presence may
arise from the proposed NMDA receptors inhibition [56]. This behavior
is based on the chemical and biological similarity with the Zn(II) ion
(valence, size, and charge and the sharing of some biological functions
in the nervous system). Additional effect can be also considered arising
from its proved SOD similar activity. Therefore, future studies are
needed to better understand all the possible steps involved in the me-
chanism by which (SerH2)2[CuCl4] acts as an antidepressant agent.
The effect of CuCl2, sertraline (SerH2Cl), and (SerH2)2[CuCl4] on
spontaneous locomotor activity was evaluated (Fig. S6A). CuCl2 salt
had dissimilar locomotor activity behavior. Sertraline behaved as ex-
pected. None of the treatments with (SerH2)2[CuCl4] showing anti-
depressant-like effect in the FST affected the activity levels when rats
were tested in an open field chamber instead of the forced swimming
cylinders during the re-test (means ± S.E.M.). This result confirms the
specificity of the FST results.
Regarding the well-known anorexigenic effect caused by sertraline,
body weight gain analysis during chronic treatments with all the
compounds were evaluated (Fig. S6B). Chronic treatment with sertra-
line induced a decrease in body weight gain in a dose-dependent
manner. Body weight was significantly lower in animals treated with
the higher dose of sertraline as compared with the control group. No
changes in body weight were observed in rats after CuCl2 or
(SerH2)2[CuCl4] administration. Thus, this compound additionally
suppresses the anorexigenic side-effect of the parent drug, a feature that
possibly constitutes an additional second clinical advantage.
3.5.2. Analgesic properties
Currently, there are several evidences related to the antinociceptive
activity exerted by antidepressants. The analgesic effect was demon-
strated in clinical studies as well as in animals submitted to different
nociceptive stimuli [15]. This effect was also noted to be independent of
its antidepressant effect [57]. Furthermore, copper complexes showed
analgesic effects [58]. These data prompted us to consider the possi-
bility that the combined administration of sertraline and copper in the
form of the (SerH2)2[CuCl4] compound may have antinociceptive ac-
tivity. Because of the scarce reported information about the analgesic
effect of sertraline, we also included this pharmaceutical in our studies.
Acute (60 min) and chronic (14 days) treatments were performed
(Fig. 8). It has to be considered that an increase in reaction time (la-
tency, sec) compared to basal (saline solution) is proportional to an-
algesic activity of the tested compounds. As it can be appreciated, in the
acute treatment (see Fig. 8), sertraline (10 mg/kg) and CuCl2 (2.7 mg/
Kg) increased the latency of licking in 30.36% and 40%, respectively.
On the contrary, at the same doses and after 14 days of treatment, those
compounds failed to augment the response latency (Fig. S7). Interest-
ingly, acute treatment with (SerH2)2[CuCl4] (Fig. 8) had a greater
antinociceptive effect (95.82%) as compared with sertraline or CuCl2
acting alone, a fact that implies an additive effect. The complex main-
tained its effect in the chronic treatment, in contrast to that observed
for the others tested compounds. The response latency increased to
76.69% when compared with the control. These findings clearly show a
significantly potentiated analgesic action (synergistic behavior) in the
(SerH2)2[CuCl4] complex. It is suggested that sustained analgesic effect
may be the result of slower and prolonged gastric absorption [16] that
could be explained because a greater lipophilicity. In the case of the
complex, it was found better albumin affinity than for sertraline alone
that favors its biological distribution (see next section). It is also pro-
posed that the enhanced analgesic activity of copper complexes can be
explained by activation of copper-dependent opioid receptors [16].
The effects of different treatments on locomotor activity are shown
in Fig. S8. In the acute treatment (Fig. S8(A)), the locomotor activity
increased after administration of sertraline and (SerH2)2[CuCl4] com-
plex. However, locomotor activity was decreased in the rats after ad-
ministration of CuCl2. In contrast, during the chronic treatment none of
the compounds affected motor activity levels in the open field chamber
(Fig. S8(B)).
These results suggest that, as is the case of others compounds, the
analgesic effect is independent of the antidepressant activity.
Furthermore, in the case of the acute treatment the increase in the lo-
comotor activity suggested that the compound did not behave in a se-
dative manner, while in the chronic treatment motor activity levels did
not significantly changes as it was expected [59].
At the end of the treatment period, none of the compounds affected
the gain in body weight as compared with the control saline compound
(Fig. S9). This is a clear advantage since some traditional analgesic
compounds provoked body weight loss.
Fig. 7. Forced swimming test (FST): effects of sertraline, CuCl2 and
(SerH2)2[CuCl4]·½H2O treatments on the behavior of the rats in the
forced swimming test (FST). Bars represent the mean number of
counts over the 5-min period of the test (± S.E.M.). *P < 0.05,
**P < 0.01, 5–10 rats per group. Saline solution; Cu (CuCl2 (1)
2.70 mg/Kg and (2) (5.40 mg/Kg); SerH2Cl (sertraline): (1)
10.0 mg/Kg and (2) 20.0 mg/Kg; (SerH2)2[CuCl4] (1): (13.3 mg/Kg)
and (SerH2)2[CuCl4] (2): 26.6 mg/Kg. Statistical analysis was car-
ried out by one-way ANOVA followed by Bonferroni's test for mul-
tiple comparisons.
Fig. 8. Hot-plate test: influence of CuCl2 (2.7 mg/Kg), SerH2Cl (sertraline, 10 mg/Kg) and
(SerH2)2[CuCl4] (13.30 mg/kg) on the reaction time (licking of hind paws) of rats. Acute
treatment. Statistical analysis was carried out by one-way ANOVA followed by Dunnett's
test.
N. Martini et al. Journal of Inorganic Biochemistry 174 (2017) 76–89
86
3.5.3. Binding affinity to albumin by fluorescence and UV–vis
spectroscopies
Serum albumin is a most important depository and transport protein
of the circulatory system, as it binds a whole variety of metabolites,
drugs, dyes and several others substances. Studies on the interactions
between serum albumin and bioactive molecules provide insight on
drug-protein binding. This type of study may have potential therapeutic
applications. Bovine serum albumin (BSA) is often used as a model
because of its close structural homology to human serum albumin
(HSA). It is well established that the reversible binding to one or very
few high-affinity sites of the albumin usually is accompanied by asso-
ciation constant (Kb) values from 104 to 106 M−1 indicating a carrier-
like behavior [60]. But additionally to the primary sites, several sites of
lower affinity are available. Therefore, a magnitude order of 103 M−1
of the binding constant value also describes the reversible character of
the interaction [61]. This range suggests an improved bioavailability of
the drugs increasing its solubility and modulating their delivery to cell
in vivo and in vitro. Thus, these kinds of studies are relevant from the
pharmacological point of view [62]. The interaction with BSA can be
studied by several methodologies and fluorescence spectroscopy is one
of the most frequently used.
The results of the quenching experiments from the interaction be-
tween (SerH2)2[CuCl4] and BSA at 25 °C and 37 °C are shown in Fig.
S10 and in Fig. 9. It could be seen that up to a maxima concentration of
100 μM, the Stern-Volmer curves were linear. Consequently, the
quenching type was probably single quenching (static or dynamic
quenching) in this range of concentration. In this study, the values of
Ksv were found to be 1.4 × 103 L·mol−1 at 25 °C and
1.29 × 103 L·mol−1 at 37 °C, being the corresponding Kq values of
1.4 × 1011 L·mol−1 and 1.29 × 1011 L·mol−1, respectively. Since the
bimolecular quenching constants (Kq) are larger than the maximum
diffusion collision quenching rate constant, the quenching was not in-
itiated from dynamic collision but from the formation of a compound.
In this case, the interactions can further be interpreted by apparent
static binding constant (Kb) and the number of binding sites (n) can be
estimated. The Kb and n per BSA at the two temperatures were listed in
Table 3.
It can be appreciated that the value of the binding constant
(≤103 M−1) of the new compound is in the expected range for the
binding of the antidepressants to BSA [10] (including sertraline with
Kb = 40.7 M−1). This effect represents an improvement in the uptake
of the complex by the albumin working at the time required for the
effective interaction of sertraline (8 h). Furthermore, the n-value of
about 1 means that there was one independent class of binding site on
the albumin for complex formation. It is worth noting that during a
short incubation time the binding of (SerH2)2[CuCl4] to BSA is stronger
than for sertraline therefore suggesting a substantially improvement of
the ability to bind albumin [10].
Following a series of studies, Ross et al. [63] proposed that the sign
of the thermodynamic parameters revealed the nature of the interaction
taking place during the formation of the complex between the studied
compound and the albumin.
The thermodynamic parameters were calculated using Van't Hoff
eq. [38,39] and the results are included in Table 3.
Τhe ΔG0 value reflects the possibility of the reaction, and ΔH0 and
ΔS0 suggest the acting forces. For temperatures varying in a small
range, the ΔH0 value can be considered as a constant.
There have been proposed four types of non-covalent interactions,
namely hydrogen bonds, van der Waals, electrostatic, and hydrophobic
interactions that play an important role in ligand binding to proteins. In
this case, negative enthalpy and entropy changes suggest the involving
of non-bonded (van der Waals) interactions and hydrogen-bond for-
mation in low dielectric media with protonation accompanying asso-
ciation. In that case, it is possible to assume that metal complexation
takes place mainly via van der Waals (stacking) interactions.
To support this finding, the interaction between the complex and
BSA was also studied by UV–vis spectroscopy (Fig. S11). It is evident
that the observed increase in the intensity of the BSA band at 280 nm
accompanied with its blue-shift suggests a change in the opening of the
structure and also the exposition of the protein residues. These changes
are in concordance with the formation of the complex between the
protein and the copper compound along with a decrease of the en-
vironment hydrophobicity [38,39].
4. Conclusions
The hydrated and anhydrous forms of two new sertraline-based salt,
consisting of a coordination complex anion containing Cu(II) and ser-
tralonium cation ((SerH2)2[CuCl4]·½H2O and (SerH2)2[CuCl4]) have
been synthesized and characterized by several physicochemical tech-
niques. Their crystal structures were solved by X-ray diffraction
methods. The sertraline molecules appear in both solid as their cationic
(SerH2+) moiety, protonated at their amine groups, and show sig-
nificant conformational flexibility. The crystal salts are further stabi-
lized by intermolecular> NH2+…[CuCl4]2− bonds and the hydrate
also presents> NH2+…Ow and Ow-H…Cl bonds. FTIR, Raman, diffuse
reflectance and UV–vis and EPR spectroscopies showed typical features
of tetrachlorocuprate(II) compounds. Antimicrobial activity of the ser-
traline-based salts was found similar to the pharmaceutical sertraline
behavior. Sertraline was able to inhibit LPO enzyme showing anti-
thyroid activity while the copper complex neither exert any inhibitory
effect nor showed ability to trap iodine. The complexes exhibit catalytic
bromination activity hence indicating that they can be considered as a
potential functional model of bromoperoxidase enzyme. Their catalytic
activity was also demonstrated because its SOD mimic ability
(IC50 = 6.3 × 10−6 M). In vivo assessment of potential pharmacolo-
gical activities showed a dose-dependent antidepressant effects of the
(SerH2)2[CuCl4] complex suppressing the anorexigenic side-effect
caused by sertraline. Acute and chronic treatments in the analgesic test
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Fig. 9. (SerH2)2[CuCl4]-BSA system: Plots of log [(F0-F)/F] vs. log [Q] at (●) 298 K and
(▲) 310 K. λex = 280 nm. [BSA] = 6 μM, (SerH2)2[CuCl4] = 0–100 μM.
Table 3
Apparent binding constants Kb, “n” binding site and relative thermodynamic parameters
of the system of (SerH2)2[CuCl4].
pH T (K) Kb (M−1) n Ra ΔH0 (KJ/
mol)
ΔG0 (KJ/
mol)
ΔS0 (J/
mol·K)
7.4 298 2,90 × 103 0,84 0,98 −87 −19,75 −225,7
310 7,47 × 102 0,91 0,99
Ra. is the correlation coefficient for the Kb values.
DS: standard deviation.
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showed increment of 30.36% to sertraline (10 mg/kg) and a 95.82%
value to (SerH2)2[CuCl4] in the latency of licking therefore indicating a
considerable analgesic action. The evaluation of the BSA binding ability
is in agreement with complex formation via van der Waals (stacking)
interactions.
It is shown that the combination of the sertraline drug with copper
produced a synergistic effect on the antidepressant activity, generating
an antianorexigenic effect, but also on the analgesic effect, the catalytic
activities against the superoxide anion and as bromoperoxidase mimic
compound.
Abbreviations
SerH2Cl Sertraline hydrochloride
SerH2+ Sertralonium cation
(SerH2)2[CuCl4] Sertralonium tetrachlorocuprate(II)
ABTS 2,2′-Azinobis(3-ethyl-benzothiazoline-6-sulfonic acid) dia-
mmonium salt
AcP Acid phosphatase
ALP Alkaline phosphatase
BSA Bovine serum albumin
DMSO Dimethyl sulfoxide
DPPH% 1,1-Diphenyl-2-picrylhydrazyl radical
EDTA Ethylenediaminetetraacetic acid
NADH Reduced nicotinamide adenine dinucleotide
NBT nitroblue tetrazolium
LPO lactoperoxidase from bovine milk
PMS phenazine methosulfate
Tris-HCl Tris(hydroxymethyl)aminomethane hydrochloride
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Appendix A. Supplementary data
(SerH2)2[CuCl4]·½H2O (CCDC 1519924): and (SerH2)2[CuCl4]
(CCDC 1519925): Tables: bond lengths and angles (Tables S1a and
S1b), atomic coordinates and equivalent isotropic displacement para-
meters (Tables S2a and S2b), anisotropic displacement parameters
(Tables S3a and S3b), hydrogen coordinates and isotropic displacement
parameters (Tables S4a and S4b), torsion angles (Tables S5a and S5b),
hydrogen bond distances and angles (Tables S6a and S6b). Figures:
FTIR spectra (Fig. S1), Raman spectra (Fig. S2), Reflectance diffuse
spectrum (Fig. S3), Electronic spectra (Fig. S4). Plot of ln([A]/[A0]) vs.
time (Fig. S5). Effects of sertraline (SerH2Cl), CuCl2 and
(SerH2)2[CuCl4] treatments on spontaneous locomotor activity (Fig.
S6A) and weight gain of rats (FST test) (Fig. S6B), Hot-plate test (Fig.
S7), Open Field test (OFT) (Fig. S8), Effects of SerH2Cl, CuCl2 and
(SerH2)2[CuCl4] treatments on weight gain of rats (analgesic test) (Fig.
S9), (SerH2)2[CuCl4]-BSA system: Plots of F0/F vs. [Q] (Fig. S10),
Electronic spectra: 200–375 nm region (albumin interaction) (Fig. S11).
Supplementary data associated with this article can be found in the
online version, at doi: http://dx.doi.org/10.1016/j.jinorgbio.2017.05.
012.
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